Loading patent…
AssigneesMerial Limited, Sanofi Pasteur Limited
InventorsGuillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
Estimating the term…
The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
A pharmaceutically acceptable salt of a linear or branched polyacrylic acid polymer, for its use as an adjuvant in a vaccine composition, characterized in that said polyacrylic acid polymer salt has a weight average molecular weight Mw in the range of 350 to 650 kDa.
An immunological or vaccine composition comprising a therapeutically effective amount of an antigen component, a pharmaceutically or veterinarily acceptable carrier, and an adjuvant comprising or consisting essentially of a non-crosslinked polyacrylic acid (PAA) polymer having a Mw from about 350 kDa to about 650 kDa, or about 400 kDa to about 500 kDa, and a polydispersity index of less than about 4 or less than about 2.
Dependencies are inferred from the claim text.